Carles Galdeano

Dr. Carles Galdeano

Facultat de Farmàcia i Ciències de l'Alimentació, Institut de Biomedicina (IBUB), Universitat de Barcelona. Av. Joan XXIII 27–31, 08028 Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CGCarles Galdeano
Carles Galdeano
MGMorgan S. Gadd
Morgan S. Gadd
PSPedro Soares
Pedro Soares
SSSalvatore Scaffidi
Salvatore Scaffidi
IMInge Van Molle
Inge Van Molle
ACAlessio Ciulli
Alessio Ciulli
E3 ubiquitin ligases are attractive targets in the ubiquitin–proteasome system, however, the development of small-molecule ligands has been rewarded with limited success. The von Hippel–Lindau protein (pVHL) is the substrate recognition subunit of the VHL E3 ligase that targets HIF-1α for degradation. We recently reported inhibitors of the pVHL:HIF-1α interaction, however they exhibited moderate potency. Herein, we report the design and optimization, guided by X-ray crystal structures, of a ligand series with nanomolar binding affinities.

4 November 2016 in Nature Communications
Verified
Journal Article
Open access
JFJulianty Frost
Julianty Frost
CGCarles Galdeano
Carles Galdeano
PSPedro Soares
Pedro Soares
MGMorgan S. Gadd
Morgan S. Gadd
KGKatarzyna M. Grzes
Katarzyna M. Grzes
ACAlessio Ciulli
Alessio Ciulli
Chemical strategies to using small molecules to stimulate hypoxia inducible factors (HIFs) activity and trigger a hypoxic response under normoxic conditions, such as iron chelators and inhibitors of prolyl hydroxylase domain (PHD) enzymes, have broad-spectrum activities and off-target effects. Here we disclose VH298, a potent VHL inhibitor that stabilizes HIF-α and elicits a hypoxic response via a different mechanism, that is the blockade of the VHL:HIF-α protein–protein interaction downstream of HIF-α hydroxylation by PHD enzymes. We show that VH298 engages with high affinity and specificity with VHL as its only major cellular target, leading to selective on-target accumulation of hydroxylated HIF-α in a concentration- and time-dependent fashion in different cell lines, with subsequent upregulation of HIF-target genes at both mRNA and protein levels. VH298 represents a high-quality chemical probe of the HIF signalling cascade and an attractive starting point to the development of potential new therapeutics targeting hypoxia signalling.

1 June 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PCPelayo Camps
Pelayo Camps
XFXavier Formosa
Xavier Formosa
CGCarles Galdeano
Carles Galdeano
TGTània Gómez
Tània Gómez
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
FLF. Javier Luque
F. Javier Luque

18 September 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
PSPedro Soares
Pedro Soares
MGMorgan S. Gadd
Morgan S. Gadd
JFJulianty Frost
Julianty Frost
CGCarles Galdeano
Carles Galdeano
LELucy Ellis
Lucy Ellis
ACAlessio Ciulli
Alessio Ciulli
The von Hippel–Lindau tumor suppressor protein is the substrate binding subunit of the VHL E3 ubiquitin ligase, which targets hydroxylated α subunit of hypoxia inducible factors (HIFs) for ubiquitination and subsequent proteasomal degradation. VHL is a potential target for treating anemia and ischemic diseases, motivating the development of inhibitors of the VHL:HIF-α protein–protein interaction. Additionally, bifunctional proteolysis targeting chimeras (PROTACs) containing a VHL ligand can hijack the E3 ligase activity to induce degradation of target proteins. We report the structure-guided design and group-based optimization of a series of VHL inhibitors with low nanomolar potencies and improved cellular permeability. Structure–activity relationships led to the discovery of potent inhibitors 10 and chemical probe VH298, with dissociation constants <100 nM, which induced marked HIF-1α intracellular stabilization. Our study provides new chemical tools to probe the VHL-HIF pathways and new VHL ligands for next-generation PROTACs.

7 August 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PCPelayo Camps
Pelayo Camps
XFXavier Formosa
Xavier Formosa
CGCarles Galdeano
Carles Galdeano
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
LRLorena Ramírez
Lorena Ramírez
FLF. Javier Luque
F. Javier Luque

10 January 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CGCarles Galdeano
Carles Galdeano
EVElisabet Viayna
Elisabet Viayna
ISIrene Sola
Irene Sola
XFXavier Formosa
Xavier Formosa
PCPelayo Camps
Pelayo Camps
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero